Literature DB >> 23390263

Is IGF-I receptor a target for autoantibody generation in Graves' disease?

Terry J Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23390263      PMCID： PMC3565121          DOI： 10.1210/jc.2013-1004

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  21 in total

Review 1.  Cellular actions of the insulin-like growth factor binding proteins.

Authors:  Sue M Firth; Robert C Baxter
Journal:  Endocr Rev       Date:  2002-12       Impact factor: 19.871

2.  Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor.

Authors:  Terry J Smith; Neil Hoa
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

3.  Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease.

Authors:  Anja K Eckstein; Marco Plicht; Hildegard Lax; Markus Neuhäuser; Klaus Mann; Sebastian Lederbogen; Christian Heckmann; Joachim Esser; Nils G Morgenthaler
Journal:  J Clin Endocrinol Metab       Date:  2006-07-11       Impact factor: 5.958

4.  Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts.

Authors:  Jane Pritchard; Noah Horst; William Cruikshank; Terry J Smith
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

5.  Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue.

Authors:  A Feliciello; A Porcellini; I Ciullo; G Bonavolontà; E V Avvedimento; G Fenzi
Journal:  Lancet       Date:  1993-08-07       Impact factor: 79.321

6.  Monoclonal antithyroglobulin antibodies derived from immunizations of mice with human eye muscle and thyroid membranes.

Authors:  T W Tao; P J Cheng; H Pham; S L Leu; J P Kriss
Journal:  J Clin Endocrinol Metab       Date:  1986-09       Impact factor: 5.958

7.  Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy.

Authors:  M N Gerding; J W van der Meer; M Broenink; O Bakker; W M Wiersinga; M F Prummel
Journal:  Clin Endocrinol (Oxf)       Date:  2000-03       Impact factor: 3.478

8.  Autoantibodies to the IGF1 receptor in Graves' orbitopathy.

Authors:  Waldemar B Minich; Nora Dehina; Tim Welsink; Christian Schwiebert; Nils G Morgenthaler; Josef Köhrle; Anja Eckstein; Lutz Schomburg
Journal:  J Clin Endocrinol Metab       Date:  2012-12-21       Impact factor: 5.958

9.  Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy.

Authors:  D R Weightman; P Perros; I H Sherif; P Kendall-Taylor
Journal:  Autoimmunity       Date:  1993       Impact factor: 2.815

10.  Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway.

Authors:  Jane Pritchard; Rui Han; Noah Horst; William W Cruikshank; Terry J Smith
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422
View more
  12 in total

Review 1.  Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.

Authors:  Yao Wang; Terry J Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-20       Impact factor: 4.799

Review 2.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

Review 3.  TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy.

Authors:  Terry J Smith
Journal:  Nat Rev Endocrinol       Date:  2015-01-06       Impact factor: 43.330

Review 4.  Graves' orbitopathy: imperfect treatments for a rare disease.

Authors:  Luigi Bartalena
Journal:  Eur Thyroid J       Date:  2013-11-20

5.  Teprotumumab for Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; George J Kahaly; Daniel G Ezra; James C Fleming; Roger A Dailey; Rosa A Tang; Gerald J Harris; Alessandro Antonelli; Mario Salvi; Robert A Goldberg; James W Gigantelli; Steven M Couch; Erin M Shriver; Brent R Hayek; Eric M Hink; Richard M Woodward; Kathleen Gabriel; Guido Magni; Raymond S Douglas
Journal:  N Engl J Med       Date:  2017-05-04       Impact factor: 91.245

Review 6.  Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

7.  Lack of Association between Selenium Status and Disease Severity and Activity in Patients with Graves' Ophthalmopathy.

Authors:  Nora Dehina; Peter Josef Hofmann; Thomas Behrends; Anja Eckstein; Lutz Schomburg
Journal:  Eur Thyroid J       Date:  2016-01-16

8.  Thyrotropin and CD40L Stimulate Interleukin-12 Expression in Fibrocytes: Implications for Pathogenesis of Thyroid-Associated Ophthalmopathy.

Authors:  Tong Wu; Tünde Mester; Shivani Gupta; Fengyuan Sun; Terry J Smith; Raymond S Douglas
Journal:  Thyroid       Date:  2016-10-18       Impact factor: 6.568

Review 9.  Extrathyroidal manifestations of Graves' disease: a 2014 update.

Authors:  Luigi Bartalena; Vahab Fatourechi
Journal:  J Endocrinol Invest       Date:  2014-06-10       Impact factor: 4.256

Review 10.  Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Front Endocrinol (Lausanne)       Date:  2017-01-03       Impact factor: 5.555
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.